0
Time From Randomization, Months
0
1.0
Proportion of Patients
Progression Free
3
6
9
12
15
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
Olaparib BRCAm
Placebo BRCAm
Number at Risk
Olaparib
BRCA
m
Placebo
BRCA
m
74
59
34
15
5
0
62
35
13
2
0
0
BRCA
m (n = 136)
Olaparib
Placebo
Events: total patients (%)
26:74 (35.1)
46:62 (74.2)
Median PFS, months
11.2
4.3
HR = 0.18
95% CI (0.10, 0.31);
P
<.00001
*
Includes 20 patients with
somatic mutations
Randomized treatment
†
Ledermann J, et al
. Lancet Oncol.
2014;15(8):852-861.
PFS in Patients With a
BRCA
Mutation
*
